HOME >> BIOLOGY >> NEWS
Protocol For Sustainable Exploitation Of Non-Timber Tropical Forest Resources Is Gaining Ground

An estimated 200 million hectares of forest were lost between 1980 and 1995, three times the state of Texas, and the yearly global deforestation rate is evaluated at about 16 million hectares. The news is not all grim, however. Forests are destroyed all over the world to make room for economic activities such as agriculture, ranching, and plantations, but overall strategies for the sustainable exploitation of non-timber plant resources are beginning to have some impact. Dr. Charles Peters, researcher at The New York Botanical Garden, has developed a protocol for the sustainable management of tropical forest resources which is now applied to dozens of projects worldwide by organizations such as the World Wildlife Fund, Conservation International, and the World Bank.

The result of Dr. Peters' twenty-year experience in tropical forest conservation, this protocol offers a blueprint for the only form of land-use in the tropics with the potential to combine the exploitation of species-rich tropical forests for profit with the preservation of their biological diversity and ecosystem functions. This is accomplished through the regular monitoring of the ecological response of a species to varying degrees of exploitation.

The protocol is guided by two fundamental assumptions: non-timber resources can be harvested sustainably from a tropical forest given sufficient information on the current stock and productivity of the species involved, and data collection and monitoring activities are most effective when conducted by local people. Following Dr. Peters' guidelines, indigenous people in remote villages of Asia, Africa, and Central and South America have become decision-making planners and data analysts, selecting products for increased extraction and monitoring the impact in order to determine the sustainable yields of their forest resources.

For example, in the rain forest of West Kalimantan, Dr.
'"/>

Contact: Annick Sullivan
asullivan@nybg.org
718-817-8815
New York Botanical Garden
2-Oct-1998


Page: 1 2

Related biology news :

1. College is first to be Kyoto Protocol compliant
2. Global change conference sets the scene for next round of Kyoto Protocol talks
3. New IIASA research challenges Kyoto Protocol
4. MIT study assesses effects of Kyoto Protocol
5. ICSU to establish Science for Sustainable Development programme
6. Sustainable Forestry Initiative Standard enhanced with new measures to protect biodiversity
7. Sustainable Harvest Of Caiman Falls Short Of Potential
8. Cocoa And Chocolate Experts Convene To Discuss Sustainable Cocoa Production
9. "Scifish" Technology To Protect Alaskas Fisheries And Promote Sustainable Use
10. Tropical legume could be alternative hay/forage crop for Texas
11. Tropical deforestation and global warming

Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: